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ABSTRACT: Background: Neuroinflammation has
received growing interest as a therapeutic target in neu-
rodegenerative disorders, including 4-repeat tauopathies.
Objectives: The aim of this cross-sectional study was to
investigate 18 kDa translocator protein positron emission
tomography (PET) as a biomarker for microglial activation
in the 4-repeat tauopathies corticobasal degeneration
and progressive supranuclear palsy.
Methods: Specific binding of the 18 kDa translocator
protein tracer 18F-GE-180 was determined by serial PET
during pharmacological depletion of microglia in a
4-repeat tau mouse model. The 18 kDa translocator pro-
tein PET was performed in 30 patients with corticobasal
syndrome (68 ± 9 years, 16 women) and 14 patients with
progressive supranuclear palsy (69 ± 9 years, 8 women),
and 13 control subjects (70 ± 7 years, 7 women). Group
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comparisons and associations with parameters of dis-
ease progression were assessed by region-based and
voxel-wise analyses.
Results: Tracer binding was significantly reduced after
pharmacological depletion of microglia in 4-repeat tau
mice. Elevated 18 kDa translocator protein labeling
was observed in the subcortical brain areas of patients
with corticobasal syndrome and progressive supra-
nuclear palsy when compared with controls and was
most pronounced in the globus pallidus internus,
whereas only patients with corticobasal syndrome
showed additionally elevated tracer binding in motor
and supplemental motor areas. The 18 kDa
translocator protein labeling was not correlated with
parameters of disease progression in corticobasal
syndrome and progressive supranuclear palsy but
allowed sensitive detection in patients with 4-repeat
tauopathies by a multiregion classifier.
Conclusions: Our data indicate that 18F-GE-180 PET
detects microglial activation in the brain of patients with
4-repeat tauopathy, fitting to predilection sites of the
phenotype. The 18 kDa translocator protein PET has a
potential for monitoring neuroinflammation in 4-repeat
tauopathies. © 2020 The Authors. Movement Disorders
published by Wiley Periodicals LLC on behalf of Interna-
tional Parkinson and Movement Disorder Society
Key Words: corticobasal syndrome; four-repeat
tauopathies; progressive supranuclear palsy; sTREM2;
translocator protein
Four-repeat (4R) tauopathies encompass a variety of
neurodegenerative diseases,1 including the movement
disorders corticobasal syndrome (CBS)2 and progressive
supranuclear palsy (PSP).3 Both are devastating neuro-
degenerative disorders, leading to death on average
within 6 to 10 years after symptom onset.1 The major-
ity of patients with CBS and PSP referred to autopsy
are characterized by intracellular aggregates of 4R tau
in neurons and astroglia.1
Neuroinflammation plays a major role in 4R
tauopathies, although there are ongoing debates on
the cause and effect of glial contribution to disease.4
Recovering reduced phagocytic activity of microglia
late in the disease course reduces tau spreading in
human brain tissue and mouse models,5,6 but
microglia and the inflammasome contribute to tau
spreading by increasing its propagation and aggrega-
tion.7,8 Thus, a better understanding of the role of
neuroinflammation across different disease stages will
be key for developing effective therapeutic strategies.
Biomarkers allowing quantification of neu-
roinflammation in 4R tauopathies could ultimately
unravel associations between neuroinflammation and
clinical progression in vivo, resulting in a monitoring
tool for immunomodulatory therapies.
Despite the incremental use of 18 kDa translocator
protein positron emission tomography (TSPO-PET)
imaging in Alzheimer’s disease9 and β-amyloid mouse
models,10,11 only 2 studies were performed so far in 4R
tauopathies,12,13 both reporting higher 11C-PK11195
binding in the subcortical target regions of patients
with PSP compared with controls. The detailed role of
TSPO as a biomarker of activated microglia in relation
to the different 4R tauopathy phenotypes and clinical
progression has yet to be explored. Furthermore, 11C
labeled radiotracers likely hamper the translation of
study results into clinical practice or therapeutic trials
because of the short half-life. The triggering receptor on
myeloid cells 2 (TREM2) is an important biomarker of
neuroinflammation,14 but despite upregulation in the
substantia nigra of deceased patients with PSP,15 there
are no relevant reports on the relevance of TREM2 in
4R tauopathies yet.
Thus, we aimed to investigate the potential of 18F-
GE-180 TSPO-PET as a biomarker of microglial activa-
tion in 4R tauopathies. Pharmacological depletion of
microglia was performed in a 4R tau mouse model to
validate the specificity of the tracer. Dynamic scanning
and noninvasive kinetic modeling in a subset of patients
served to determine short acquisition windows for low
patient burden and cost-effective TSPO-PET imaging.
Finally, we recruited a substantial number of patients
with 4R tauopathy and controls to test the capability of
18F-GE-180 TSPO-PET to detect elevated microglia
activation in patients with CBS and PSP and to study
associations of TSPO labeling with parameters of dis-
ease progression. TREM2 and the albumin quotient
were assessed in cerebrospinal fluid (CSF) to compare
18F-GE-180 TSPO-PET quantification with markers of
disease associated microglia and blood–brain barrier
integrity.
Material and Methods
TSPO-PET Imaging Before and After Microglia
Depletion in a 4R Tau Mouse Model
All animal experiments were performed in compli-
ance with the National Guidelines for Animal Protec-
tion, Germany, and with the approval of the regional
animal committee (Regierung von Oberbayern) over-
seen by a veterinarian. Small animal PET (μPET) exper-
iments were carried out in 5 female human tau P301S
mice, a mouse line expressing the human 0N4R tau iso-
form with the P301S mutation in exon 10 of MAPT
gene under control of the murine thy1 promoter.16
Strong elevation of TSPO labeling in the brainstem, the
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cerebellum, the hippocampus, and the cortex of P301S
mice versus wild-type at 6.5 months of age was
observed previously.17 TSPO-μPET examinations were
performed at baseline (7 months of age) and during
microglial depletion after PLX5622 administration for
7 weeks. The sample size calculation was based on the
in-house TSPO-PET quantification in the same model17
with the baseline acting as control to archive a power
(1–β) of 0.80 at α of 0.05. PLX5622 was provided by
Plexxikon (Berkeley, CA) and formulated in AIN-76A
standard chow by Research Diets (New Brunswick, NJ)
at 1200 ppm. μPET imaging was performed as reported
previously.18 After coregistration to a magnetic reso-
nance imaging (MRI) mouse atlas as described previ-
ously,19 normalization of images to standardized
uptake value (SUV) images was conducted. Predefined
bilateral cortical (24 mm3), brainstem (12 mm3), and
whole brain (500 mm3) target volumes of interest were
used, and SUVs were compared between baseline and
follow-up. Details are provided in the Supporting
Information.
Study Design, Study Population, and Clinical
Assessments
A total of 30 patients with possible (n = 12) or proba-
ble (n = 18) CBS, 14 patients with possible (n = 1) or
probable (n = 13) PSP–Richardson syndrome according
to Armstrong Clinical Research and Movement Disor-
ders Society criteria, respectively,2,20 and 13 β-amyloid
negative control subjects without objectified cognitive
impairment and with intact motor function were
included in the analysis at the Ludwig-Maximilians-
Universität (LMU) Munich between September 2017
and January 2020 (Fig. S1, Table 1). A total of 3
patients with 4R tauopathy (n = 2 CBS, n = 1 PSP) and
1 control were excluded prior to the analysis as a result
of low-affinity TSPO binding as revealed by genotyping
of the rs6971 single nucleotide polymorphism (SNP).
Exclusion of low-affinity binders was performed
because of lower 18F-GE-180 binding in controls when
compared with controls with medium-affinity or high-
affinity binding status (unpublished data). Only patients
who were β-amyloid negative and controls were
included in the analysis. A total of 9 patients with CBS
were excluded as a result of β-amyloid positivity in 18F-
flutemetamol PET, and 4 patients with PSP because of
a non-Richardson syndrome/non-CBS phenotype prior
to the analysis. The study and the data analyses (ethics
applications 17–569, 17–755, and 19–022) were
approved by the local ethics committee (LMU-Munich,
Germany). All participants provided written informed
consent according to the Declaration of Helsinki. Clini-
cal data were collected according to the German multi-
center prospective ProPSP cohort study.21 Disease
duration was defined as the time between symptom
onset and PET imaging. The PSP Rating Scale (PSPRS)
served as the disease severity parameter, and the Mon-
treal Cognitive Assessment (MoCA) was used to assess
the severity of cognitive deficits. Schwab and England
Activities of Daily Living were recorded as a global
score of functional ability.
Human PET Imaging
TSPO-PET Acquisition and Preprocessing
Patients were scanned at the Department of Nuclear
Medicine, LMU, using a Biograph 64 PET/CT scanner
(Siemens, Erlangen, Germany) and a bolus injection of
189 ± 12 MBq 18F-GE-180. Details are provided in the
Supporting Information. 18F-GE-180 PET imaging was
performed in a full dynamic setting (0–90 minutes post
injectionem) for a mixed population of 11 patients with
4R tauopathies (6 CBS, 5 PSP) to allow noninvasive
kinetic modeling and evaluation of a suitable time win-
dow for patient comfort and economic imaging. All
TABLE 1. Demographics at the group level
Demographics 4RT CBS PSP-RS Controls
n 44 30 14 13
Age 68.3 ± 8.6 68.3 ± 9.1 68.8 ± 8.0 70.3 ± 7.5
Sex 24 ♀ / 20 ♂ 16 ♀ / 14 ♂ 8 ♀ / 6 ♂ 7 ♀ / 6 ♂
rs6971 HAB: 30 / MAB: 14 HAB: 22 / MAB: 8 HAB: 8 / MAB: 6 HAB: 5 / MAB: 8
PSPRS 31.8 ± 13.4 29.7 ± 13.4 36.5 ± 12.7 n.a.
Disease duration (m) 32.7 ± 26.0 30.8 ± 21.9 36.7 ± 33.8 n.a.
MoCA 22.4 ± 5.7 22.4 ± 4.7 aP = 0.001 22.2 ± 7.8 aP = 0.004 29.1 ± 1.0
SEADL 60.0 ± 18.2 60.7 ± 18.0 58.6 ± 19.2 n.a.
Armstrong criteria – 12 possible CBS, 18 probable CBS – –
MDS PSP criteria – 7 not fulfilled, 4 suspected PSP-CBS, 19 possible PSP-CBS 1 possible PSP, 13 probable PSP –
aSignificant group differences between CBS and PSP groups against controls followed by the specific P value.
Demographics were statistically tested by analysis of variance or χ2 test.
Abbreviations: 4RT, 4-repeat tauopathies; CBS, corticobasal syndrome; PSP, progressive supranuclear palsy; RS, Richardson syndrome; HAB, high-affinity
binder; MAB, medium-affinity binder; PSPRS, PSP Rating Scale; n.a., not available; m, months; n, sample size; MoCA, Montreal Cognitive Assessment; SEADL,
Schwab and England Activities of Daily Living; MDS, Movement Disorder Society.
Data are presented as n or mean ± SD.
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other patients and controls received a static 60-minute
to 80-minute p.i. scan. The SUVs of the 60-minute to
80-minute p.i. images of all 44 patients with 4R
tauopathies were averaged and compared with the aver-
age SUV of the 13 controls by calculating a percentage
difference map. After visual and quantitative inspection
(application of Hammers atlas regions), the bilateral
antero-lateral temporal lobe was deemed suitable for
further evaluation as a pseudo-reference tissue (distribu-
tion volume ratios: distribution volume ratio (DVR)
and SUV ratios [SUVr]) as it showed no differences
between patients with 4R tauopathies and controls and
low variance. For dynamic data sets, the Logan refer-
ence tissue model in PMOD22 was used to calculate
DVR images (for details, see the Supporting
Information).
TSPO-PET Data Analysis
The 18F-GE-180 DVR and SUVr values were
obtained in 7 subcortical target regions23 defined by the
atlas of the basal ganglia,24 including an additional
manually drawn midbrain target region25 and 12 corti-
cal target regions as predefined by the Hammer’s atlas26
in the Montreal Neurology Institute space. The selec-
tion of target regions was based on earlier autopsy
studies.27,28 All target regions are listed in Table 2.
Single-frame SUVr values of dynamic data sets were
correlated with 0-minute to 90-minute DVR deriving
from Logan graphical analysis. For target region-based
group analyses, the maximum 18F-GE-180 SUVr value
of bilateral target regions was used to account for
potential side asymmetries.
Statistical parametric mapping (V8; University Col-
lege of London, London, UK) running in Matlab ver-
sion R2011a (MathWorks Inc., Natick, MA) was used
for voxel-wise statistical analyses. Group comparisons
of 18F-GE-180 SUVr images of the full 4R tauopathy
cohort as well as CBS and PSP patient groups versus
controls were performed by an unpaired t test using
age, sex, and the TSPO polymorphism as covariates.
Topological false discovery rate correction for multiple
comparisons29 with a significance threshold of P < 0.05
was applied.
β-amyloid-PET Acquisition and Analysis
All CBS and control subjects underwent static 18F-
flutemetamol PET imaging from 90 to 110 minutes
p.i. as described previously using the same PET scanner.
Images were dichotomized into positive or negative by
a visual read of a single nuclear medicine expert
supported by regional z scores in the frontal, parietal,
and temporal target regions as derived by the Gold soft-
ware package (V4.17; HERMES Medial Solutions,
Stockholm, Sweden).
DNA Extraction and SNP Genotyping
rs6971 SNP genotyping was performed as described
previously (for details, see the Supporting Information).
sTREM2 and Albumin Measures
sTREM2 concentration was measured in the avail-
able CSF samples (18 patients with CBS and 12 con-
trols) by a modified assay based on the previously
described sTREM2 enzyme-linked immunosorbent
assay using the MSD platform.30,31 This assay was
designed to selectively detect sTREM2 coming from
cleavage of the full-length protein (for details, see the
Supporting Information). Raw values are provided as
ng/mL. The CSF/serum albumin ratio was measured as
the gold-standard marker of blood–brain barrier
integrity.
Statistics
SPSS (V25; IBM, Ehningen, Germany) was used for
statistical testing. P values <0.05 were considered
significant.
Mouse Study
18F-GE-180 SUV of P301S mice were compared
between baseline and microglial depletion by a paired
Student t test.
Methodology
In the subset of human dynamic scans, the agreement
between DVR and SUVr of different time frames was
assessed by a Pearson coefficient of correlation (R). In
the full human data set, coefficients of variance were
calculated and compared between 60-minute and 80-
minute p.i. 18F-GE-180 SUV and SUVr (paired Student
t test).
Demographics
Age, PSPRS, disease duration, and MoCA scores
were compared between the different study groups
(CBS, PSP, controls) by a 1-way analysis of variance,
whereas sex and the rs6971 polymorphism were subject
to a χ2 test.
Group Comparisons
The 18F-GE-180 SUVr of predefined target regions
(maximum value of bilateral regions) were compared
between the 4 study groups (4R tauopathies, CBS, PSP,
controls) by a multivariate analysis of covariance
including age, sex, and rs6971 polymorphism as
covariates. False discovery rate correction for multiple
brain regions as well as post hoc Bonferroni correction
for multiple testing of groups was applied. For region-
based classification, regional SUVr ≥ mean value +2
standard deviations of the controls were defined as pos-
itive. Here, 1 positive target region defined the subject
as positive (dichotomous) and sensitivity and specificity
of TSPO-PET for detection of CBS and PSP was calcu-
lated. A summed z score vector was calculated for all
patients with 4R tauopathies by the addition of single-
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region z scores ([individual SUVr patient – mean value
SUVr controls]/standard deviation SUVr controls). A
total of 9 regions (putamen, external and internal parts
of the globus pallidus, subthalamic nucleus, substantia
nigra, midbrain, precentral gyrus, middle frontal gyrus,
inferior frontal gyrus) with significant differences of
TSPO-PET binding at the group level were included in
the z score vector to obtain a global but 4R tauopathy–
specific measure of microglial activation. A univariate
analysis of covariance including age and sex as
covariates was performed for comparison of log-
transformed sTREM2 measures and the CSF/serum
albumin ratio between patients with CBS and controls.
Correlation Analyses
Partial correlations were calculated for 18F-GE-180
SUVr in predefined regions and the summed z score
vector with clinical severity (PSPRS), disease duration,
and MoCA controlled for age, sex, and rs6971 poly-
morphism, and including false discovery rate correc-
tions for multiple tests in predefined regions (n = 60
tests) within CBS and PSP subgroups. Partial correla-
tions were calculated for sTREM2 with clinical sever-
ity (PSPRS), disease duration, and MoCA controlled
for age and sex. Flexible fitting models were calcu-
lated between the summed z score vector and
sTREM2 or the CSF/serum albumin ratio for patients
with CBS.
Results
Specificity of 18F-GE-180 to 4R Tau–
Associated Microglia and Implementation of
an Efficient TSPO-PET Scan Protocol
P301S 4R tau mice were imaged before and after
microglial depletion by a CSF1R inhibitor. CSF1R
blocking strongly reduced 18F-GE-180 binding in the
whole brain of 5 P301S mice and model-specific target
regions (Fig. 1A,B), indicating specific detection of acti-
vated microglia by the tracer. Immunohistochemistry
confirmed microglial depletion >90% by Iba1.
Dynamic imaging in patients with 4R tauopathies
indicated a moderate brain uptake and fast wash out
in 4R tauopathy target regions and the temporal ref-
erence region (Fig. 1C). SUVr tended to plateau after
60 minutes postinjection (Fig. 1D), similar to earlier
observations in rodents.18 Agreement between Logan
DVR from kinetic modeling and single-frame SUVr
reached R > 0.6, starting >6 minutes postinjection
and dropped toward R < 0.5 for frames >80 minutes
postinjection (Fig. 1E). 60-minute to 80-minute SUVr
overestimated 0-minute to 90-minute DVR by
22.2% ± 4.9% (cortical) and 29.5% ± 11.0% (sub-
cortical), but both correlated in a near linear fashion
for cortical (R = 0.91, P < 0.001) and subcortical
(R = 0.85, P < 0.001) target regions (Fig. 1F). Visual
TABLE 2. TSPO-PET quantification at the group level
Subcortical 4RT, n = 44 CBS, n = 30 PSP-RS, n = 14 HC, n = 13
Putamen 0.934 (0.904–0.963) aP = 0.009 0.940 (0.904–0.976) aP = 0.010 0.920 (0.868–0.973) 0.822 (0.767–0.876)
Globus pallidus externus 0.978 (0.949–1.007) aP = 0.001 0.987 (0.952–1.023) aP = 0.001 0.960 (0.908–1.011) aP = 0.038 0.831 (0.777–0.885)
Globus pallidus internus 1.047 (1.013–1.080) aP = 4.28e-5 1.048 (1.007–1.090) aP = 1.52e-4 1.043 (0.983–1.103) aP = 0.002 0.843 (0.781–0.906)
Thalamus 1.031 (0.999–1.062) 1.042 (1.003–1.081) 1.008 (0.951–1.064) 0.949 (0.890–1.008)
Subthalamic nucleus 1.112 (1.069–1.155) aP = 0.003 1.119 (1.066–1.172) aP = 0.004 1.097 (1.021–1.174) aP = 0.046 0.921 (0.842–1.001)
Substantia nigra 1.068 (1.035–1.101) aP = 0.004 1.068 (1.027–1.108) aP = 0.009 1.068 (1.009–1.127) aP = 0.042 0.926 (0.865–0.988)
Dentate nucleus 0.981 (0.946–1.015) 0.979 (0.935–1.022) 0.985 (0.922–1.047) 0.881 (0.817–0.946)
Midbrain 1.086 (1.049–1.122) aP = 0.005 1.087 (1.042–1.133) aP = 0.010 1.082 (1.016–1.148) aP = 0.049 0.936 (0.868–1.004)
Cortical 4RT, n = 44 CBS, n = 30 PSP-RS, n = 14 HC, n = 13
Precentral gyrus 0.917 (0.892–0.943) 0.928 (0.897–0.958) aP = 0.036 0.896 (0.852–0.941) 0.842 (0.796–0.889)
Superior frontal gyrus 0.881 (0.857–0.904) 0.892 (0.863–0.920) 0.858 (0.816–0.899) 0.827 (0.783–0.871)
Middle frontal gyrus 0.887 (0.863–0.912) aP = 0.020 0.894 (0.864–0.925) aP = 0.017 0.873 (0.829–0.917) 0.802 (0.756–0.847)
Inferior frontal gyrus 0.973 (0.951–0.995) aP = 0.028 0.974 (0.946–1.001) aP = 0.040 0.970 (0.931–1.010) 0.899 (0.858–0.940)
Straight gyrus 0.997 (0.964–1.029) 0.990 (0.949–1.030) 1.011 (0.952–1.069) 0.906 (0.846–0.967)
Anterior cingulate gyrus 0.959 (0.931–0.987) 0.965 (0.931–1.000) 0.946 (0.895–0.996) 0.905 (0.852–0.957)
Anterior orbital gyrus 1.104 (1.075–1.133) 1.096 (1.060–1.132) 1.119 (1.067–1.172) 1.036 (0.982–1.091)
Medial orbital gyrus 1.124 (1.096–1.151) 1.123 (1.089–1.157) 1.125 (1.076–1.174) 1.045 (0.994–1.095)
Lateral orbital gyrus 1.219 (1.176–1.263) 1.214 (1.160–1.268) 1.230 (1.152–1.308) 1.098 (1.017–1.179)
Posterior orbital gyrus 1.161 (1.131–1.190) 1.166 (1.129–1.202) 1.151 (1.097–1.204) 1.085 (1.030–1.140)
Postcentral gyrus 0.892 (0.868–0.916) 0.899(0.870–0.929) 0.876 (0.833–0.920) 0.841 (0.796–0.886)
Parietal lobe 0.915 (0.892–0.937) 0.928 (0.901–0.955) 0.888 (0.848–0.927) 0.866 (0.824–0.907)
aSignificant differences of patient groups against controls are followed by the specific P value.
Values represent regional group means of TSPO-PET standardized uptake value ratios (60-minute to 80-minute time window) and their 95% confidence intervals
in predefined subcortical and cortical brain areas. P values were derived from multivariate analysis of variance with age, sex, and rs6971 polymorphism as
covariates. All P values were false discovery rate corrected for multiple comparisons (n = 20 brain regions) and Bonferroni post hoc corrections for multiple study
groups.
Abbreviations: TSPO-PET, translocator protein positron emission tomography; 4RT, 4-repeat tauopathies; CBS, corticobasal syndrome; PSP, progressive supra-
nuclear palsy; RS, Richardson syndrome; HC, controls without objectified memory impairment and with intact motor function.
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FIG. 1. Preclinical validation of tracer specificity and methodological considerations for human 4-repeat (4R) tauopathy translocator protein positron
emission tomography (TSPO-PET) imaging. Mouse study: (A) Coronal (striatal layer) and axial 18F-GE-180 TSPO-PET images of P301S mice on a mag-
netic resonance imaging standard template show strong decreases of the cerebral tracer uptake in week 7 of microglia depletion (DPL) when compared
with baseline (BL). Images represent the average standardized uptake value (SUV) of n = 5 P301S mice. (B) Spaghetti plots show individual TSPO-PET
SUV changes between baseline and a state of depleted microglia in target regions of P301S mice. P values are derived from paired Student t tests.
Human study: Values derived from n = 11 4R tauopathy patients (n = 6 corticobasal syndrome, n = 5 progressive supranuclear palsy) (C–F). (C) Time-
activity curves of 4R tauopathy target regions (mean value ± standard deviation of 19 brain regions) and a temporal lateral pseudo-reference tissue. (D)
Time-activity ratio curves of 4R tauopathy target regions divided by binding in the pseudo-reference tissue (mean value ± standard deviation of 19 brain
regions). (E) Agreement between distribution volume ratios (DVR) and SUV ratios (SUVr) in single frames during the 90-minute scan duration. Each dot
represents the mean Pearson correlation coefficient (R) of 19 4R tauopathy target regions. (F) Agreement of DVR with 60-minute to 80-minute SUVr of
cortical and subcortical 4R tauopathy target regions as quantified at the single patient level. (G) Individual examples of visual agreement between DVR
and 60-minute to 80-minute SUVr for a patient with corticobasal syndrome (CBS; 58-year-old man; PSP Rating Scale, 27; disease duration, 37 months;
Montreal Cognitive Assessment, 14) and a patient with progressive supranuclear palsy–Richardson syndrome (PSP-RS; 74-year-old man; PSP Rating
Scale, 18; disease duration, 10 months; Montreal Cognitive Assessment, 22). Axial planes of 18F-GE-180 TSPO-PET images are projected on a stan-
dard magnetic resonance imaging atlas. (H) Percentage difference maps of n = 44 4R tauopathy patients (4RT) and n = 13 healthy controls (HC) for
SUV and SUVr quantification of the 18F-GE-180 TSPO-PET group average. Percentage differences are projected in axial and sagittal planes on a stan-
dard magnetic resonance imaging atlas. (I) Coefficients of variance in the contrast of SUV and SUVr quantification. Bars represent mean Coefficients of
variance values ± standard deviation of cortical (n = 12) and subcortical (n = 7) 4R tauopathy target regions. P values are derived from a paired Student
t test. [Color figure can be viewed at wileyonlinelibrary.com]
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image analysis revealed highly similar uptake pat-
terns of DVR and SUVr maps for cortical and subcor-
tical TSPO labeling in patients with 4R tauopathies
(Fig. 1G). Percentage difference maps of SUV and
SUVr indicated a high similarity of magnitude
(Fig. 1H), but intersubject variance was significantly
decreased in the control and 4R tauopathy groups by
the SUVr approach (Fig. 1I).
TSPO Labeling Follows the Expected Topology
in Patients with CBS and PSP
All demographics and disease parameter are provided
in Table 1. There were no significant differences in age,
sex, rs6971 polymorphism, disease severity, or disease
duration between patients with CBS and PSP. Both 4R
tauopathy patient groups were matched for age, sex,
and rs6971 polymorphism when compared with con-
trols. MoCA was significantly reduced in patients with
CBS (22.4 ± 4.7, P = 0.001) and patients with PSP
(22.2 ± 7.8, P = 0.004) when compared with controls
(29.1 ± 1.0).
TSPO-PET SUVs in the temporal pseudo-reference
region were not different between 4R tauopathy high-
affinity binder (HAB; 0.52 ± 0.07), 4R tauopathy
medium-affinity binder (MAB; 0.55 ± 0.09), control
HAB (0.52 ± 0.07), and control MAB (0.54 ± 0.03; all
P = nonsignificant; Fig. S2). Predefined regions of
interest indicated significantly higher TSPO-PET SUVr
in the subcortical (putamen, internal and external part
of the globus pallidus, subthalamic nucleus, substantia
nigra, and midbrain) and cortical brain areas (middle
frontal gyrus and inferior frontal gyrus) of patients
with 4R tauopathies when compared with controls
after false discovery rate correction for multiple com-
parisons and adjustment for age, sex, and the rs6971
polymorphism (Table 2). The strongest elevation of
TSPO-PET SUVr in the combined 4R tauopathy
cohort was observed in the internal part of the globus
pallidus (1.047; 95% confidence interval [CI],
1.013–1.080) when compared with controls (0.843;
95% CI, 0.781–0.906; P < 0.001, false discovery rate
corrected; Table 2). Patients with CBS and PSP pheno-
types indicated increased TSPO labeling in the major-
ity of subcortical target areas when compared with
controls (Table 2). The group of patients with a CBS
phenotype also showed significantly elevated TSPO-
PET SUVr versus controls in the cortical regions of the
frontal lobe, including the precentral gyrus, the middle
frontal gyrus, and the inferior frontal gyrus, whereas
patients with a PSP phenotype did not show elevated
cortical TSPO-PET SUVr versus control subjects
(Table 2).
Statistical parametric mapping validated higher TSPO
labeling in the entire group of patients with 4R
tauopathies versus control subjects and were most
pronounced in the midbrain and the pons, the globus
pallidus, the dentate nucleus. Cortical areas of patients
with 4R tauopathies indicated higher TSPO labeling
when compared with controls and were most pro-
nounced in the motor and supplemental motor cortices
(Fig. 2A, Table S1A). Patients with CBS showed an ele-
vated TSPO labeling in the cortical areas, including
motor and supplemental motor cortices, whereas the
patients with PSP did not. Subcortical TSPO labeling
was increased in the CBS and PSP subgroups (compare
Fig. 2B and Fig. 2C, Table S1B,C).
TSPO Labeling Allows Sensitive Detection of
Patients with 4R Tauopathies and Occurs in
Agreement with an Asymmetric CBS
Phenotype
TSPO labeling in predefined regions of interest did
not show associations with parameters of disease pro-
gression (Table S4, Supporting Information Results). A
multiregion classifier indicated sensitivities of 80% and
79% for patients with CBS and PSP at a specificity of
92% (Fig. S3, Supporting Information Results).
Of 30 patients with CBS, 18 indicated a right periph-
eral predominance of clinical symptoms, 11 showed a
predominant left phenotype, and 1 was affected
equilaterally. Asymmetry indices of TSPO-PET in the
subcortical regions showed a significant lateralization
to the hemisphere contralateral of the clinical pheno-
type (49/77, χ2 = 5.11, P = 0.024), with highest agree-
ment in the internal (15/18, χ2 = 8.10, P = 0.004) and
external (9/9, χ2 = 9.00, P = 0.003) parts of the globus
pallidus. Asymmetry indices of TSPO-PET in the frontal
cortex were not significantly associated with lateraliza-
tion of the clinical phenotype (49/98, χ2 = 1.98,
P = 0.160).
sTREM2 Peaks at Low TSPO Labeling in CBS
A subpopulation of 18 patients with CBS and 12 con-
trols was eligible for CSF sTREM2 measures. There
was no difference in absolute sTREM2 levels between
patients with CBS and controls (0.96 [95% CI,
0.89–1.04] vs. 0.96 [95% CI, 0.86–1.05], P = 0.950;
Fig. 3A). Measures of sTREM2 in patients with CBS as
a function of TSPO labeling described an inverted U-
shape with a peak at low TSPO-PET signal in the com-
bined and cortical target regions, but not in subcortical
target regions (Fig. 3B,C, Supporting Information
Fig. S4A). In TSPO-positive patients (>2 SD of con-
trols), there was a negative linear association between
TSPO labeling and sTREM2 (R = −0.616, P = 0.016).
There was no significant association between parame-
ters of disease progression and sTREM2 (Fig. 3D-F).
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TSPO Labeling Is Not Associated with Blood–
Brain Barrier Integrity
To test for a dependency of 18F-GE-180 binding on
dysfunctional blood–brain barrier integrity, we com-
pared the CSF/serum albumin ratio with the individ-
ual z score vector of TSPO labeling in patients with
CBS. There was no significant difference of the
CSF/serum albumin ratio between patients with CBS
and controls (6.8 [95% CI, 5.8–7.7] vs. 6.1 [95% CI,
4.6–7.6], P = 0.501; Fig. 3G). TSPO-PET z score vec-
tors were not significantly different between
5 patients with CBS with dysfunctional blood–brain
barriers and 20 patients with CBS with normal
CSF/serum albumin ratios (16.0 [95% CI, 4.0–27.9]
vs. 20.7 [95% CI, 15.2–26.2], P = 0.480; Fig. 3H).
TSPO-PET z score vectors in patients with CBS and
the CSF/serum albumin ratio did not show any sig-
nificant associations (Fig. 3I,J, Fig. S4B).
Discussion
We provide the first human study using a fluorinated
TSPO-PET radiotracer in a meaningful sized cohort of
patients with CBS and PSP. Our translational data in a
4R tauopathy mouse model verified that 18F-GE-180
detects 4R tau–related microglial activation with high
specificity. Dynamic imaging and methodological
workup in humans indicated feasibility of TSPO-PET
imaging with low patient effort and simplified quantifi-
cation approaches. Patients with CBS and PSP revealed
elevated TSPO labeling in subcortical brain regions,
whereas patients with CBS additionally showed stron-
ger elevation of TSPO labeling in the forebrain. Cross-
sectional correlation analyses indicated only minor
associations of TSPO labeling with parameters of dis-
ease progression but a potential of TSPO-PET as an
early disease stage biomarker in CBS.
To the best of our knowledge, there are only 2 publi-
shed reports on TSPO-PET imaging in 4R tauopathies,
both only including patients with PSP,12,13 whereas our
study is the first including CBS. A study from 2006
investigated a small cohort of 4 patients with PSP using
11C-PK11195 and implementing serial imaging in
2 patients.12 Their baseline findings of the strongest
TSPO-PET increases in the basal ganglia and brainstem
are in line with our observations in 14 patients with
PSP, whereas we could not confirm differences in the
frontal cortex. A more recent study scanned 16 patients
with PSP with a mean PSPRS score of 40.8 with 11C-
PK11195 together with an equal number of patients
with Alzheimer’s disease and 13 controls and found
higher TSPO labeling in the putamen, thalamus, and
pallidum in the patients with PSP compared with con-
trols, but no binding differences versus Alzheimer’s dis-
ease.13 Our regional findings in 14 patients with PSP of
similar disease severity (mean PSPRS score, 36.5) con-
firm the earlier observations using a third-generation
TSPO tracer. Our novel TSPO-PET data in CBS mirror
the subcortical findings of PSP, but reveal an additional
elevation of TSPO labeling in the neocortex with the
strongest signal in the motor and supplemental motor
areas of the forebrain. This fits well to the pronounced
cortical phenotype of CBS compared with PSP and is
also in line with the concept of overlapping neuropa-
thology among different 4R tauopathies.32
Recently, 18F-GE-180 to assess TSPO labeling in
patients with glioma and multiple sclerosis was criti-
cized because of inferior image quality and limited
uptake across the blood–brain barrier.33-35 This reflects
an important topic since blood–brain barrier integrity
can be disturbed in neurodegenerative disorders.36
Based on our preclinical experience, we were aware of
a high correlation of the 18F-GE-180 PET signal with
immunohistochemistry in mouse models of neurodegen-
erative disorders despite the low brain penetration of
the tracer.11,18,37 Although we deemed it unlikely that a
parallel blood–brain barrier phenomenon caused these
strong associations, we made use of pharmacological
microglial depletion to prove specificity of the tracer for
activated microglia in presence of 4R tau. As expected,
we observed a clear decrease of the 18F-GE-180 PET
signal in microglia depleted P301S mice when com-
pared with their own individual baseline. This strongly
supports the claim of a specific 18F-GE-180 PET signal
in vivo and recent human in vivo blocking data
supported specific detection of microglia by this tracer
further.38 In addition, we did not find any association
of the CSF/serum albumin ratio as the gold-standard
marker for blood–brain barrier integrity and TSPO
labeling. Thus, we have no evidence that a blood–brain
barrier breakdown causes the binding patterns of 18F-
GE-180. Furthermore, the binding patterns fit to the
neuropathological topologies of CBS and PSP in former
autopsy studies.27,39,40
Including corrections for multiple comparisons, we
did not find significant associations between measures
of disease progression and regional TSPO labeling in
CBS and PSP, controlling for age, sex, and rs6971 poly-
morphism. Yet, although our 18F-GE-180 PSP findings
did not reach significance, they were roughly in line
with positive associations of 11C-PK11195 binding and
disease severity in a cohort of 16 patients with PSP,
showing a similarly large interindividual heterogeneity
of TSPO labeling at a given PSPRS score.13 In contrast,
the regional associations of TSPO labeling with param-
eters of disease progression in CBS showed an equal or
higher TSPO-PET signal in the early stages of disease
progression. This could indicate a saturation of micro-
glial activation in the late stages of CBS, which is
known in the presence of amyloidosis.41 We found a
sensitivity of 75% in patients with possible CBS and
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even higher sensitivity for probable CBS and PSP versus
controls using a simple semiquantitative multiregion
classifier, underlining the potential of TSPO-PET as a
supportive biomarker for diagnosis of 4R tauopathies
and improving limited sensitivity of clinical diagnosis.42
Despite the lacking association between TSPO labeling
and parameters of disease progression, we find a clear
agreement between asymmetries of subcortical TSPO
labeling and contralateral clinical predominance of the
CBS phenotype. This supports the important role of
microglial activation in the pathophysiological cascade
of 4R tauopathies.4 A subpopulation of patients with
CBS and controls was eligible for CSF sTREM2 mea-
sures, but missing differences between patients and con-
trols suggest that CSF TREM2 measures appear less
sensitive when compared with a detailed work-up of
TREM2 in brain regions in autopsy.15 However, we
find an interesting negative association between TSPO-
PET and sTREM2 in patients with CBS after a
sTREM2 peak at low levels of TSPO. Speculatively, this
could indicate a functional burnout of microglia with
increasing activity and deserves further longitudinal
exploration. The observed cross-sectional heterogeneity
of TSPO labeling in patients with 4R tauopathies will
enable predictive analyses, aiming to elucidate if high
or low TSPO labeling at baseline is associated with bet-
ter clinical outcome. Taken together, longitudinal PET
studies and predictive analyses of the clinical course are
needed for further exploration of TSPO-PET as a bio-
marker in immunomodulatory trials. The current 4R
FIG. 2. Voxel-based differences of translocator protein positron emission tomography binding in 4R tauopathy patients. Color coding shows brain areas
with increased translocator protein positron emission tomography binding in groups of all patients with (A) 4-repeat (4R) tauopathy (n = 44), (B) cor-
ticobasal syndrome (CBS; n = 30), and (C) progressive supranuclear palsy–Richardson syndrome patients (PSP-RS; n = 14) when compared with
healthy controls (HC; n = 13). The t statistics are derived from an unpaired Student t test with age, sex, and rs6971 polymorphism as covariates as cal-
culated by statistical parametric mapping (SPM). The lower threshold reflects a significance level of P = 0.05 after false discovery rate correction for
multiple comparisons. The lower threshold for C was adjusted to B to improve visual comparability of differences in patients with CBS and PSP.
Extracerebral voxels are masked. The T score maps are projected in axial and sagittal planes on a standard magnetic resonance imaging atlas. [Color
figure can be viewed at wileyonlinelibrary.com]
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tauopathy cohort will be followed clinically and by
serial TSPO-PET to address this question.
Among the limitations of our study we note missing
autopsy validation of the studied clinically diagnosed
4R tauopathy cases. However, the high specificity of a
clinical 4R tauopathy diagnosis predicts a low number
of false positive cases in the studied data set.42 We
acknowledge as another limitation that we did not
FIG. 3. Soluble triggering receptor on myeloid cells 2 (sTREM2) and blood–brain barrier integrity in patients with corticobasal syndrome (CBS). (A) Com-
parison of sTREM2 between patients with CBS and controls, controlled for age and sex. (B,C) Associations between multiregional translocator protein
(TSPO) labeling and sTREM2 in patients with CBS for all brain regions with significant differences in TSPO– positron emission tomography (PET) (B)
and a subanalysis in cortical regions (C). R/p values are derived from quadratic fits. (D–F) Associations between parameters of disease progression and
sTREM2 in patients with CBS. (G) Comparison of the cerebrospinal fluid (CSF) to serum quotient of albumin (CSF/serum albumin ratio) between
patients with CBS and controls. (H) Comparison of TSPO labeling between patients with CBS with an abnormal and a normal CSF/serum albumin ratio.
Associations between the CSF/serum albumin ratio and multiregional TSPO labeling in patients with CBS for all brain regions with significant differ-
ences in TSPO-PET (I) and a subanalysis in cortical regions (J). R/p values are derived from partial correlation, controlled for age, sex, and rs6971. A
subanalysis of subcortical regions is provided in Figure S4. MoCA, Montreal Cognitive Assessment. [Color figure can be viewed at
wileyonlinelibrary.com]
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include arterial sampling in the dynamic imaging proto-
col, thus although we deem it unlikely, we cannot
exclude effects from differences in plasma fractions and
tracer metabolism among our study groups. Medium-
and high-affinity binders were not equally distributed
among the study groups. Since a subanalysis in
medium- and high-affinity binders was not sufficiently
powered, we included the binding status as a covariate,
and we note that a remaining bias on the TSPO-PET
quantification cannot be fully excluded. β-amyloid PET
was not performed in the PSP arm of the study because
of the high clinical probability of predicting a 4R
tauopathy. Thus, we cannot rule out frequent43
β-amyloid copathology and a subsequent impact on
microglial activation in patients with PSP, which, how-
ever, does not have a major impact on clinical
progression.
Conclusion
TSPO-PET imaging closely reflects the expected
topology of microglial activation in 4R tauopathies and
shows potential as a neuroinflammation biomarker.
in vivo assessment of TSPO labeling has a potential to
support early diagnosis of 4R tauopathies, facilitating
increased sensitivity. Longitudinal studies are needed to
explore the value of TSPO-PET imaging as a progres-
sion biomarker in 4R tauopathies.
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